Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab as First Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  2/9/2016
Wilshire Oncology Medical Group
mi
from
La Verne, CA
A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab as First Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 2/9/2016
Wilshire Oncology Medical Group
mi
from
La Verne, CA
Click here to add this to my saved trials
A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab as First Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  2/9/2016
UCSF Comprehensive Cancer Center
mi
from
San Francisco, CA
A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab as First Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 2/9/2016
UCSF Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab as First Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  2/9/2016
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab as First Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 2/9/2016
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab as First Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  2/9/2016
Ellis Fischel Cancer Center
mi
from
Columbia, MO
A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab as First Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 2/9/2016
Ellis Fischel Cancer Center
mi
from
Columbia, MO
Click here to add this to my saved trials
A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab as First Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  2/9/2016
Weill Medical College of Cornell University
mi
from
New York, NY
A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab as First Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 2/9/2016
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab as First Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  2/9/2016
Local Institution
mi
from
Besancon Cedex,
A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab as First Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 2/9/2016
Local Institution
mi
from
Besancon Cedex,
Click here to add this to my saved trials
Phase II Trial Evaluating the Efficacy and Tolerability of Aprepitant & Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting
A Multi-Center, Open-Label Trial to Evaluate the Efficacy and Tolerability of Aprepitant and Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Colorectal Cancer (CRC) Patients Receiving FOLFOX or FOLFIRI Chemotherapy
Status: Enrolling
Updated:  2/9/2016
St. Josephs/Cander Hospital
mi
from
Savannah, GA
Phase II Trial Evaluating the Efficacy and Tolerability of Aprepitant & Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting
A Multi-Center, Open-Label Trial to Evaluate the Efficacy and Tolerability of Aprepitant and Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Colorectal Cancer (CRC) Patients Receiving FOLFOX or FOLFIRI Chemotherapy
Status: Enrolling
Updated: 2/9/2016
St. Josephs/Cander Hospital
mi
from
Savannah, GA
Click here to add this to my saved trials
Phase II Trial Evaluating the Efficacy and Tolerability of Aprepitant & Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting
A Multi-Center, Open-Label Trial to Evaluate the Efficacy and Tolerability of Aprepitant and Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Colorectal Cancer (CRC) Patients Receiving FOLFOX or FOLFIRI Chemotherapy
Status: Enrolling
Updated:  2/9/2016
Kaiser Permanente
mi
from
Hilo, HI
Phase II Trial Evaluating the Efficacy and Tolerability of Aprepitant & Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting
A Multi-Center, Open-Label Trial to Evaluate the Efficacy and Tolerability of Aprepitant and Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Colorectal Cancer (CRC) Patients Receiving FOLFOX or FOLFIRI Chemotherapy
Status: Enrolling
Updated: 2/9/2016
Kaiser Permanente
mi
from
Hilo, HI
Click here to add this to my saved trials
Phase II Trial Evaluating the Efficacy and Tolerability of Aprepitant & Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting
A Multi-Center, Open-Label Trial to Evaluate the Efficacy and Tolerability of Aprepitant and Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Colorectal Cancer (CRC) Patients Receiving FOLFOX or FOLFIRI Chemotherapy
Status: Enrolling
Updated:  2/9/2016
Ingalls Memorial Hospital
mi
from
Harvey, IL
Phase II Trial Evaluating the Efficacy and Tolerability of Aprepitant & Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting
A Multi-Center, Open-Label Trial to Evaluate the Efficacy and Tolerability of Aprepitant and Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Colorectal Cancer (CRC) Patients Receiving FOLFOX or FOLFIRI Chemotherapy
Status: Enrolling
Updated: 2/9/2016
Ingalls Memorial Hospital
mi
from
Harvey, IL
Click here to add this to my saved trials
Phase II Trial Evaluating the Efficacy and Tolerability of Aprepitant & Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting
A Multi-Center, Open-Label Trial to Evaluate the Efficacy and Tolerability of Aprepitant and Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Colorectal Cancer (CRC) Patients Receiving FOLFOX or FOLFIRI Chemotherapy
Status: Enrolling
Updated:  2/9/2016
Kansas City Cancer Center
mi
from
Kansas City, MO
Phase II Trial Evaluating the Efficacy and Tolerability of Aprepitant & Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting
A Multi-Center, Open-Label Trial to Evaluate the Efficacy and Tolerability of Aprepitant and Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Colorectal Cancer (CRC) Patients Receiving FOLFOX or FOLFIRI Chemotherapy
Status: Enrolling
Updated: 2/9/2016
Kansas City Cancer Center
mi
from
Kansas City, MO
Click here to add this to my saved trials
Phase II Trial Evaluating the Efficacy and Tolerability of Aprepitant & Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting
A Multi-Center, Open-Label Trial to Evaluate the Efficacy and Tolerability of Aprepitant and Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Colorectal Cancer (CRC) Patients Receiving FOLFOX or FOLFIRI Chemotherapy
Status: Enrolling
Updated:  2/9/2016
OHSU Knight Cancer Institute
mi
from
Portland, OR
Phase II Trial Evaluating the Efficacy and Tolerability of Aprepitant & Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting
A Multi-Center, Open-Label Trial to Evaluate the Efficacy and Tolerability of Aprepitant and Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Colorectal Cancer (CRC) Patients Receiving FOLFOX or FOLFIRI Chemotherapy
Status: Enrolling
Updated: 2/9/2016
OHSU Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
Phase II Trial Evaluating the Efficacy and Tolerability of Aprepitant & Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting
A Multi-Center, Open-Label Trial to Evaluate the Efficacy and Tolerability of Aprepitant and Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Colorectal Cancer (CRC) Patients Receiving FOLFOX or FOLFIRI Chemotherapy
Status: Enrolling
Updated:  2/9/2016
Texas A & M university / Scott and White Clinic
mi
from
Temple, TX
Phase II Trial Evaluating the Efficacy and Tolerability of Aprepitant & Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting
A Multi-Center, Open-Label Trial to Evaluate the Efficacy and Tolerability of Aprepitant and Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Colorectal Cancer (CRC) Patients Receiving FOLFOX or FOLFIRI Chemotherapy
Status: Enrolling
Updated: 2/9/2016
Texas A & M university / Scott and White Clinic
mi
from
Temple, TX
Click here to add this to my saved trials
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
A Phase II, Open Label Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  2/9/2016
Georgetn Univ Lombardi Can Ctr
mi
from
Washington,
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
A Phase II, Open Label Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 2/9/2016
Georgetn Univ Lombardi Can Ctr
mi
from
Washington,
Click here to add this to my saved trials
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
A Phase II, Open Label Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  2/9/2016
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
A Phase II, Open Label Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 2/9/2016
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
A Phase II, Open Label Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  2/9/2016
University of Miami
mi
from
Miami, FL
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
A Phase II, Open Label Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 2/9/2016
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
A Phase II, Open Label Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  2/9/2016
University of Michigan
mi
from
Ann Arbor, MI
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
A Phase II, Open Label Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 2/9/2016
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
A Phase II, Open Label Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  2/9/2016
Wayne State University
mi
from
Detroit, MI
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
A Phase II, Open Label Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 2/9/2016
Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
A Phase II, Open Label Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  2/9/2016
Ellis Fischel Cancer Center
mi
from
Columbia, MO
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
A Phase II, Open Label Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 2/9/2016
Ellis Fischel Cancer Center
mi
from
Columbia, MO
Click here to add this to my saved trials
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
A Phase II, Open Label Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  2/9/2016
Cancer Centers of the Carolinas
mi
from
Greenville, SC
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
A Phase II, Open Label Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 2/9/2016
Cancer Centers of the Carolinas
mi
from
Greenville, SC
Click here to add this to my saved trials
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
A Phase II, Open Label Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  2/9/2016
Seattle Cancer Care Alliance
mi
from
Seattle, WA
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
A Phase II, Open Label Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 2/9/2016
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
A Phase II, Open Label Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  2/9/2016
West Virginia University
mi
from
Morgantown, WV
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
A Phase II, Open Label Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 2/9/2016
West Virginia University
mi
from
Morgantown, WV
Click here to add this to my saved trials
A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer
A Phase I Study of Ixabepilone Administered as a Daily Oral Dose on 5 Successive Days Every 21 Days in Subjects With Advanced Cancer
Status: Enrolling
Updated:  2/9/2016
Georgetown University Medical Center Lombardi Cancer Center
mi
from
Washington,
A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer
A Phase I Study of Ixabepilone Administered as a Daily Oral Dose on 5 Successive Days Every 21 Days in Subjects With Advanced Cancer
Status: Enrolling
Updated: 2/9/2016
Georgetown University Medical Center Lombardi Cancer Center
mi
from
Washington,
Click here to add this to my saved trials
A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer
A Phase I Study of Ixabepilone Administered as a Daily Oral Dose on 5 Successive Days Every 21 Days in Subjects With Advanced Cancer
Status: Enrolling
Updated:  2/9/2016
Wayne State University (Hwcrc)
mi
from
Detroit, MI
A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer
A Phase I Study of Ixabepilone Administered as a Daily Oral Dose on 5 Successive Days Every 21 Days in Subjects With Advanced Cancer
Status: Enrolling
Updated: 2/9/2016
Wayne State University (Hwcrc)
mi
from
Detroit, MI
Click here to add this to my saved trials
BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase I Dose-Escalating, Open-Label, Non-Placebo Controlled Study of BAY 43-9006 (Sorafenib) in Combination With Carboplatin, Paclitaxel and Bevacizumab in Previously Untreated Patients With Stage IIIB (With Malignant Pleural Effusions) or Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  2/9/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase I Dose-Escalating, Open-Label, Non-Placebo Controlled Study of BAY 43-9006 (Sorafenib) in Combination With Carboplatin, Paclitaxel and Bevacizumab in Previously Untreated Patients With Stage IIIB (With Malignant Pleural Effusions) or Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 2/9/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Birmingham Hematology and Oncology Associates, LLC
mi
from
Birmingham, AL
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Birmingham Hematology and Oncology Associates, LLC
mi
from
Birmingham, AL
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Hematology Oncology Associates
mi
from
Phoenix, AZ
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Hematology Oncology Associates
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Northern Arizona Hematology & Oncology Associates
mi
from
Sedona, AZ
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Northern Arizona Hematology & Oncology Associates
mi
from
Sedona, AZ
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Arizona Oncology Associates D.B.A. Hematology Oncology
mi
from
Tucson, AZ
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Arizona Oncology Associates D.B.A. Hematology Oncology
mi
from
Tucson, AZ
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Southwest Cancer Care
mi
from
Murrieta, CA
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Southwest Cancer Care
mi
from
Murrieta, CA
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Florida Cancer Institute
mi
from
Hudson, FL
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Florida Cancer Institute
mi
from
Hudson, FL
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Ocala Oncology Center
mi
from
Ocala, FL
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Ocala Oncology Center
mi
from
Ocala, FL
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Cancer Centers of Florida
mi
from
Ocoee, FL
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Cancer Centers of Florida
mi
from
Ocoee, FL
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Cancer Care & Hematology Specialists of Chicagoland
mi
from
Niles, IL
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Cancer Care & Hematology Specialists of Chicagoland
mi
from
Niles, IL
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Central Indiana Cancer Centers
mi
from
Carmel, IN
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Central Indiana Cancer Centers
mi
from
Carmel, IN
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Hope Center
mi
from
Terre Haute, IN
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Hope Center
mi
from
Terre Haute, IN
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Maryland Oncology Hematology PA
mi
from
Columbia, MD
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Maryland Oncology Hematology PA
mi
from
Columbia, MD
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Alliance Hematology Oncology PA.
mi
from
Westminster, MD
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Alliance Hematology Oncology PA.
mi
from
Westminster, MD
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Minnesota Oncology and Hematology, PA
mi
from
Minneapolis, MN
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Minnesota Oncology and Hematology, PA
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Missouri Cancer Associates
mi
from
Columbia, MO
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Missouri Cancer Associates
mi
from
Columbia, MO
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Kansas City Cancer Center
mi
from
Kansas City, MO
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Kansas City Cancer Center
mi
from
Kansas City, MO
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Arch Medical Services
mi
from
St. Louis, MO
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Arch Medical Services
mi
from
St. Louis, MO
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Comprehensive Cancer Center of Nevada
mi
from
Henderson, NV
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Comprehensive Cancer Center of Nevada
mi
from
Henderson, NV
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Hematology-Oncology Assoc. Of Northern Nj, Pa
mi
from
Morristown, NJ
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Hematology-Oncology Assoc. Of Northern Nj, Pa
mi
from
Morristown, NJ
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
New Mexico Cancer Care Associates
mi
from
Santa Fe, NM
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
New Mexico Cancer Care Associates
mi
from
Santa Fe, NM
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
New York Oncology Hematology, P.C.
mi
from
Amsterdam, NY
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
New York Oncology Hematology, P.C.
mi
from
Amsterdam, NY
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Interlakes Oncology/Hematology PC
mi
from
Rochester, NY
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Interlakes Oncology/Hematology PC
mi
from
Rochester, NY
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Regional Cancer Care, PA
mi
from
Durham, NC
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Regional Cancer Care, PA
mi
from
Durham, NC
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Raleigh Hematology Oncology Associates
mi
from
Raleigh, NC
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Raleigh Hematology Oncology Associates
mi
from
Raleigh, NC
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Cancer Centers of the Carolinas
mi
from
Greenville, SC
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Cancer Centers of the Carolinas
mi
from
Greenville, SC
Click here to add this to my saved trials
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated:  2/9/2016
Texas Cancer Center
mi
from
Arlington, TX
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients
Status: Enrolling
Updated: 2/9/2016
Texas Cancer Center
mi
from
Arlington, TX
Click here to add this to my saved trials